Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-1 MP weekly intravenous augmentation therapy in alpha-1 antitrypsin deficiency emphysema
2013-001870-38Phase 3Active
- Sponsor
- Grifols
- Start
- Sep 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency emphysema and alpha-1 antitrypsin deficiency (AATD) (3 arms), sponsored by Grifols. Primary endpoint: Progression of lung tissue loss by CT densitometry PD15. Started Sep 2013; status: active.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency emphysemaalpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2013-001870-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001870-38.